ERK inhibitors

US9884048B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Phieng Siliphaivanh · Newton, US
• Joey L. Methot · Westwood, US
• Kathryn Lipford · Boston, US
• Danielle F. Molinari · Brookline, US
• David L. Sloman · Brookline, US
• David J. Witter · Norfolk, US
• Hua Zhou · Acton, US
• Christopher W. Boyce · Flemington, US
• Xianhai Huang · Hackettstown, US
• Jongwon Lim · Lexington, US
• David Joseph Guerin · Natick, US
• Ganesh Babu Karunakaran · Bengaluru, IN
• Raman K. Bakshi · Edison, US
• Ziping Liu · Forestville, CA
• Jianmin Fu · Beijing, CN
• Zhilong Wan · Beijing, CN
• Wei Liu · Exton, US

Key dates

• Filing date: Dec 10, 2015
• Grant date: Feb 6, 2018
• Expiry date: Dec 10, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides a compound of Formula (I) or the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are ERK2 inhibitors. The invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of Formula (I) and a pharmaceutically acceptable carrier. The invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of Formula (I) and an effective amount of at least one other pharmaceutically active ingredient (such as, for example, a chemotherapeutic agent), and a pharmaceutically acceptable carrier.